Prokidney Corp
Veridion Score
BETALOW CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PROK moving today?
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PROK overview
Related filings and maps
Congress activity in PROK
No receipt-qualified Congressional disclosure is present for PROK in the cached public ledger.
PROK contract awards, year to date.
Public federal awards linked to this ticker.
PROK lobbying filings, year to date.
Registered lobbying filings matched to Prokidney Corp.